Yahya BÜYÜKAŞIK, Hakan GÖKER, Hatime Arzu YAŞAR, Olgu Erkin ÇINAR, Nur YAZDALI KÖYLÜ, İbrahim BARIŞTA

Central nervous system involvement in patients with acute myeloid leukemia

Background/aim: To evaluate the incidence, clinical features, risk factors, and prognosis of central nervous system (CNS) involvement in patients with acute myeloid leukemia (AML). Materials and methods: All AML patients who were admitted to Hacettepe University hospital between 2000 and 2021 were evaluated. The medical records of 548 AML cases were retrospectively analyzed. Results: The frequency of CNS involvement was 2.4% (n = 13) at diagnosis and 4.6% (n = 25) at diagnosis or during follow-up. Parenchymal involvement was seen in 5 patients, leptomeningeal involvement was seen in 11 patients. Three patients had both leptomeningeal and parenchymal involvements, and 6 patients had optic nerve or ocular involvement. In univariate analysis, younger age and extramedullary involvement at diagnosis were associated with CNS disease at diagnosis, and extramedullary involvement at diagnosis was associated with CNS disease during follow-up. In multivariate analysis; younger age and extramedullary involvement at diagnosis were associated with CNS disease at diagnosis and during follow-up respectively. Median overall survival was 5.4 months in patients with CNS disease at diagnosis and 16.9 months in patients with CNS disease during follow-up and 16.2 months in patients with no CNS disease. Conclusion: CNS disease is a rare complication of AML. Younger age and extramedullary involvement at diagnosis are risk factors for CNS involvement.Keywords: Acute myeloid leukemia, central nervous system involvement, risk factors

PDF

___

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: a Cancer Journal for Clinicians 2019; 69 (1): 7-34. doi:10.3322/ caac.21551
2. Castagnola C, Nozza A, Corso A, Bernasconi C. The value of combination therapy in adult acute myeloid leukemia with central nervous system involvement. Haematologica 1997; 82 (5): 577-580.
3. Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017; 129 (4): 424-447. doi:10.1182/blood-2016-08-733196
4. Cassileth PA, Sylvester LS, Bennett JM, Begg CB. High peripheral blast count in adult acute myelogenous leukemia is a primary risk factor for CNS leukemia. Journal of Clinical Oncology 1988; 6 (3): 495-498. doi:10.1200/JCO.1988.6.3.495
5. Holmes R, Keating MJ, Cork A, Broach Y, Trujillo J et al. A unique pattern of central nervous system leukemia in acute myelomonocytic leukemia associated with inv(16)(p13q22). Blood 1985; 65 (5): 1071-1078
6. Shihadeh F, Reed V, Faderl S, Medeiros LJ, Mazloom A et al. Cytogenetic profile of patients with acute myeloid leukemia and central nervous system disease. Cancer 2012; 118 (1): 112- 117. doi:10.1002/cncr.26253
7. Rozovski U, Ohanian M, Ravandi F, Garcia-Manero G, Faderl S et al. Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia. Leukemia & Lymphoma 2015; 56 (5): 1392-1397. doi:10.3109/10428194.2014.953148
8. Alakel N, Stolzel F, Mohr B, Kramer M, Oelschlagel U et al. Symptomatic central nervous system involvement in adult patients with acute myeloid leukemia. Cancer Management and Research 2017; 9: 97-102. doi:10.2147/CMAR.S125259
9. Jabbour E, Guastad Daver N, Short NJ, Huang X, Chen HC et al. Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia. American Journal of Hematology 2017; 92 (9): 924- 928. doi:10.1002/ajh.24799
10. Seymour JF, Pierce SA, Kantarjian HM, Keating MJ, Estey EH. Investigation of karyotypic, morphologic and clinical features in patients with acute myeloid leukemia blast cells expressing the neural cell adhesion molecule (CD56). Leukemia 1994; 8 (5): 823-826.
11. Chang H, Brandwein J, Yi QL, Chun K, Patterson B et al. Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome. Leukemia Research 2004; 28 (10): 1007-1011. doi:10.1016/j. leukres.2004.01.006
12. Vogler WR, Velez-Garcia E, Weiner RS, Flaum MA, Bartolucci AA et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. Journal of Clinical Oncology 1992; 10 (7): 1103-1111. doi:10.1200/JCO.1992.10.7.1103
13. Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009; 113 (9): 1875-1891. doi:10.1182/blood-2008-04-150250
14. Abbott BL, Rubnitz JE, Tong X, Srivastava DK, Pui CH et al. Clinical significance of central nervous system involvement at diagnosis of pediatric acute myeloid leukemia: a single institution’s experience. Leukemia 2003; 17 (11): 2090-2096. doi:10.1038/sj.leu.2403131
15. Johnston DL, Alonzo TA, Gerbing RB, Aplenc R, Woods WG et al. Central nervous system disease in pediatric acute myeloid leukemia: A report from the Children’s Oncology Group. Pediatric Blood & Cancer 2017; 64 (12). doi:10.1002/pbc.26612
16. Felix A, Leblanc T, Petit A, Nelkem B, Bertrand Y et al. Acute myeloid leukemia with central nervous system involvement in children: experience from the French protocol analysis ELAM02. Journal of Pediatric Hematology/Oncology 2018; 40 (1): 43-47. doi:10.1097/MPH.0000000000001034
17. Del Principe MI, Buccisano F, Soddu S, Maurillo L, Cefalo M et al. Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome. Seminars in Hematology 2018; 55 (4): 209-214. doi:10.1053/j. seminhematol.2018.02.006
18. Cheng CL, Li CC, Hou HA, Fang WQ, Chang CH et al. Risk factors and clinical outcomes of acute myeloid leukaemia with central nervous system involvement in adults. BioMed Central cancer Cancer 2015; 15: 344. doi:10.1186/s12885-015-1376-9
19. Martinez-Cuadron D, Montesinos P, Perez-Sirvent M, Avaria A, Cordon L et al. Central nervous system involvement at first relapse in patients with acute myeloid leukemia. Haematologica 2011; 96 (9): 1375-1379. doi:10.3324/haematol.2011.042960
20. Stewart DJ, Keating MJ, McCredie KB, Smith TL, Youness E et al. Natural history of central nervous system acute leukemia in adults. Cancer 1981; 47 (1): 184-196.
21. Zheng C, Liu X, Zhu W, Cai X, Wu J et al. Tailored central nervous system-directed treatment strategy for isolated CNS recurrence of adult acute myeloid leukemia. Hematology 2014; 19 (4): 208-212. doi:10.1179/1607845413Y.0000000117
22. Sanders KE, Ha CS, Cortes-Franco JE, Koller CA, Kantarjian HM et al. The role of craniospinal irradiation in adults with a central nervous system recurrence of leukemia. Cancer 2004; 100 (10): 2176-2180. doi:10.1002/cncr.20280